Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cytomegalovirus Disease01:27

Cytomegalovirus Disease

47
Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
47
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

327
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
327
Tonsillitis II: Management01:26

Tonsillitis II: Management

612
This lesson will focus on the different treatment options for managing tonsillitis, which typically depend on the cause and severity.
612
Pneumonia IV: Management01:28

Pneumonia IV: Management

1.1K
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
1.1K
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

367
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
367
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

636
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
636

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ubiquitination Defect of XIAP as Novel Susceptibility to Invasive Fungal Pneumonia.

The Journal of infectious diseases·2026
Same author

International Survey on Screening and Management of Strongyloidiasis in Solid Organ Transplant Patients.

Transplant infectious disease : an official journal of the Transplantation Society·2026
Same author

Severity of Respiratory Syncytial Virus and Other Respiratory Viruses Versus Seasonal Influenza Among Hospitalized Patients With Cancer.

Open forum infectious diseases·2025
Same author

A Retrospective Study on the Use of Daptomycin and Linezolid in Singapore General Hospital.

Antibiotics (Basel, Switzerland)·2025
Same author

Acute Fever Early Post Renal Transplantation-A Call From the Tropics.

Transplant infectious disease : an official journal of the Transplantation Society·2025
Same author

Management of mould pneumonia in resource-limited settings in Asia: A Delphi-based consensus statement by the Asia Fungal Working Group.

Medical mycology·2025

Related Experiment Video

Updated: Apr 12, 2026

Use of In vivo Imaging to Monitor the Progression of Experimental Mouse Cytomegalovirus Infection in Neonates
05:53

Use of In vivo Imaging to Monitor the Progression of Experimental Mouse Cytomegalovirus Infection in Neonates

Published on: July 6, 2013

15.6K

Cytomegalovirus Treatment.

Ban Hock Tan1

  • 1Department of Infectious Diseases, Singapore General Hospital The Academia, 20 College Road, Singapore, 169856 Singapore ; Duke-NUS Graduate Medical School, Singapore, Singapore.

Current Treatment Options in Infectious Diseases
|May 23, 2015
PubMed
Summary

Effective cytomegalovirus (CMV) treatment requires distinguishing pre-emptive therapy from established disease management. Novel agents like CMX001 offer new hope against drug-resistant CMV infections.

Keywords:
CMX001adoptive immunotherapycidofovircytomegalovirusdrug resistanceencephalitisfoscarnetganciclovirmaribavirpneumonitispre-emptive therapyretinitisvalganciclovir

More Related Videos

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System
10:24

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System

Published on: October 5, 2015

13.0K
Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus
11:18

Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus

Published on: May 7, 2012

13.4K

Related Experiment Videos

Last Updated: Apr 12, 2026

Use of In vivo Imaging to Monitor the Progression of Experimental Mouse Cytomegalovirus Infection in Neonates
05:53

Use of In vivo Imaging to Monitor the Progression of Experimental Mouse Cytomegalovirus Infection in Neonates

Published on: July 6, 2013

15.6K
Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System
10:24

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System

Published on: October 5, 2015

13.0K
Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus
11:18

Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus

Published on: May 7, 2012

13.4K

Area of Science:

  • Virology
  • Immunology
  • Pharmacology

Background:

  • Cytomegalovirus (CMV) infection management necessitates differentiating between pre-emptive treatment and established disease, which includes viral syndromes and tissue-invasive conditions.
  • Treatment strategies vary based on disease severity and patient status, with oral valganciclovir for mild cases and intravenous ganciclovir or foscarnet for severe tissue-invasive disease.

Approach:

  • Intravenous ganciclovir or foscarnet are preferred for severe CMV syndromes, dosed according to renal function until symptom resolution and viral load clearance.
  • Close patient monitoring for drug side effects and treatment response is essential during CMV therapy.
  • Addressing drug-resistant CMV may involve combination therapy (ganciclovir and foscarnet) or unconventional agents like leflunomide or maribavir.

Key Points:

  • Immune reconstitution through reduced immunosuppression or antiretroviral therapy is a critical component of CMV management.
  • CMX001, a novel agent active against double-stranded viruses, shows promise as it does not confer cross-resistance with ganciclovir or foscarnet.
  • Prophylaxis or pre-emptive treatment with CMX001 may preserve the efficacy of ganciclovir or foscarnet for treating established CMV disease.

Conclusions:

  • Optimal management of cytomegalovirus (CMV) infection hinges on accurate diagnosis and tailored therapeutic approaches.
  • Emerging agents like CMX001 present a valuable strategy for overcoming treatment challenges posed by drug-resistant CMV strains.
  • Integrating immune reconstitution strategies alongside antiviral therapy is crucial for long-term patient outcomes in CMV infections.